Allergy Therapeutics - Appointment of Executive Chairman
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company" or "Group")
Appointment of Executive Chairman
Helge Weiner-Trapness, who has been Chief Strategy Officer and an Executive Director of the Group since
In his new role Helge will provide additional corporate and strategic leadership alongside
Peter who has served on the Board since 2010 and as Chairman since 2011, has overseen a period of considerable transformation for the Group, with notable commercial and clinical progress, through a shifting regulatory landscape for allergy immunotherapies. He will continue to serve on the Board as a Non-Executive Director to allow a smooth transition and will not stand for re-election at the next Annual General Meeting. The Board extends its gratitude and appreciation for his contribution and leadership.
Helge Weiner-Trapness, newly appointed Executive Chairman of Allergy Therapeutics, said: "On behalf of the Board, I would like to thank Peter for his outstanding contributions and leadership over so many years. The strength and resilience of the Company today are testament to his commitment and significant efforts. Allergy Therapeutics has established a leading position in its core markets, with a significant portfolio and an innovative pipeline that present a strong platform for future growth. I look forward to working closely with Manuel, the Board and the management team as we pursue our growth ambitions and advance our international strategy, including through the potential dual listing in
Peter Jensen OBE, outgoing Chairman of Allergy Therapeutics, said: "It has been an immense privilege to serve as Chairman of Allergy Therapeutics Plc. Together with my colleagues on the Board and the whole Company team, we have built Allergy Therapeutics into a leading international commercial biotechnology business, and I am proud of what we have achieved together. The recent launch of Grassmuno® in
Market Abuse Regulation
This announcement contains inside information for the purposes of the
For further information, please contact:
Allergy Therapeutics
+44 (0)1903 845 820
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
+44 (0)20 7220 0500
ICR Healthcare
+44 (0)20 3709 5700
allergytherapeutics@icrhealthcare.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company, headquartered in the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE